Ignacio Provencio is a Professor of Biology at the University of Virginia. His research focuses on melanopsin-based photoreception and its role in non-visual light responses, including circadian rhythm regulation, fear modulation, and glaucoma pathophysiology. His lab investigates melanopsin signaling pathways and their broader implications for vertebrate physiology. Education: B.A., Swarthmore College, 1987 Ph.D., University of Virginia, 1996 Postdoctoral Research, Uniformed Services University, 1996–1999 Key research interests include: Melanopsin phototransduction mechanisms Role of intrinsically photosensitive retinal ganglion cells (ipRGCs) in non-image-forming vision Impact of light on circadian rhythms and neurodegenerative diseases like glaucoma Light’s influence on fear behavior and weight regulation Recent work highlights: ipRGC survival in glaucoma models Melanopsin’s role in weight loss under dietary challenges Clinical applications of melanopsin-based light therapy His research spans in vivo and in vitro studies, integrating molecular, cellular, and behavioral approaches to understand light’s multifaceted effects on physiology.
Nancy Papalopulu is Professor of Developmental Neuroscience in the Faculty of Life Sciences at the University of Manchester, where she leads research on cell state transitions and gene expression dynamics during development. Currently holding a Wellcome Trust Investigator Award (2022-2027), she has been a prominent figure in developmental neuroscience for over two decades, previously serving as a Wellcome Trust Senior Research Fellow from 2006-2022 and at the Wellcome Trust/Cancer Research UK Gurdon Institute in Cambridge from 2000-2006. Her research focuses on understanding how cells transition from progenitor states to differentiation with precise timing, or enter quiescence from which they may be reactivated. Using single cell quantitative approaches, live imaging, multiple experimental model systems (including Xenopus, zebrafish, and stem cell cultures), and mathematical modeling, her lab investigates the dynamics of gene expression that underlie cell fate decisions. A key contribution has been the hypothesis that the mutually antagonistic interaction between the neural progenitor transcription factor Hes1 and microRNA miR-9 generates pulsatile gene expression at the single cell level, which can transition to stable states in a time-controlled manner. Analysis of her recent publications reveals a strong focus on oscillatory gene expression patterns, neural development mechanisms, and the role of dynamics in cell fate determination. Her work spans developmental neuroscience, cancer biology (particularly glioblastoma), and pancreatic development, demonstrating the broad applicability of her research on gene expression dynamics. Scientific Awards and Recognition: Wellcome Trust Investigator Award (2022-2027) Wellcome Trust Senior Research Fellow (2006-2022) Wellcome Trust Senior Research Fellow (2000-2006) Wellcome Trust Career Development Fellow (1997-2000) Post-doctoral Fellow, Human Frontier Science Program Organization (1991-1996) Professor Papalopulu supervises multiple PhD students and postdoctoral researchers through various funding mechanisms including Wellcome Trust, MRC, and CRUK. Her current projects include 'A quantitative and dynamical approach to understanding cell state transitions' (2022-2027), 'Decoding Pulsing Proteins in the Pancreas' (2018-2022), and participation in the Centre for Biological Timing. Her laboratory team consists of postdocs, PhD students, and technicians working collaboratively on multiple aspects of developmental dynamics. The Papalopulu Lab maintains a strong presence in the field with 88 research outputs and active collaborations across multiple institutions. Her work contributes to UN Sustainable Development Goals related to good health and well-being through advancing fundamental understanding of developmental processes that underlie tissue formation, maintenance, and disease.
Satchidananda Panda is a Professor at the Salk Institute for Biological Studies, leading the Regulatory Biology Laboratory. His research focuses on circadian rhythms and their impact on health, metabolism, and disease. He discovered the role of melanopsin in regulating circadian clocks and pioneered studies on time-restricted eating (TRE), showing its benefits in preventing obesity, diabetes, and metabolic disorders. His work integrates basic science with translational research, leveraging clinical trials and wearable technology to improve public health. Education: PhD in Molecular Biology from The Scripps Research Institute (2001), Postdoctoral Research at Genomics Institute of the Novartis Research Foundation (2001-2005). Research Interests: Circadian regulation of metabolism, sleep, and aging. Key discoveries include the molecular mechanisms of light sensing, circadian disruption's role in chronic diseases, and TRE's therapeutic potential. Current projects explore TRE's applications in shift workers, cancer patients, and individuals with metabolic syndrome. Key Innovations: Developed the MyCircadianClock app to collect global data on eating/sleep patterns, enabling large-scale studies. Collaborates with the Wu Tsai Human Performance Alliance to explore exercise and circadian health links. Awards: 2023 AAAS Fellow, 2014 Julie Martin Mid-Career Award, 2006 Dana Foundation Award, and Pew Scholar honor (2006). Labs/Teams: Panda Lab at Salk focuses on multi-omics analysis and translational studies. Active in clinical trials testing TRE in firefighters, shift workers, and diabetic patients.
Scott A. Read is a Professor in the School of Optometry at Queensland University of Technology's Faculty of Health. He is a leading researcher in the field of myopia development and control, with extensive expertise in ocular biometry, choroidal thickness measurements, and optical coherence tomography applications. His work bridges basic vision science and clinical optometry, focusing on understanding the mechanisms of eye growth and developing strategies for myopia management. Dr. Read's research program centers on myopia development and control, with particular emphasis on choroidal thickness dynamics, ocular biometry changes during visual tasks, and the effects of light exposure on eye growth. His work reveals that the choroid plays a critical role as an optical signal transducer in eye growth regulation, with significant diurnal variations and responses to visual stimuli. He has extensively documented how myopic defocus, accommodation, and light exposure patterns influence choroidal thickness and axial elongation in children and young adults. His research has established important links between outdoor light exposure and reduced myopia progression, contributing significantly to evidence-based myopia control strategies. Analysis of Dr. Read's recent publications shows a strong focus on advanced imaging techniques, particularly optical coherence tomography and its applications in measuring choroidal thickness, vascular changes, and biomechanical properties of the eye. His work increasingly incorporates artificial intelligence methods for image analysis while maintaining a strong clinical orientation toward understanding myopia mechanisms and developing effective control strategies. His research spans from fundamental investigations of visual processing pathways to clinical trials of myopia control interventions like atropine therapy. Dr. Read has been instrumental in several major collaborative efforts, including the International Myopia Institute reports that have shaped global understanding of myopia mechanisms and control strategies. His work has been foundational in establishing the choroid's role as a key tissue in eye growth regulation and myopia development. Through his laboratory at QUT, Dr. Read mentors numerous PhD students and early-career researchers, fostering the next generation of vision scientists. His research team employs a multidisciplinary approach combining optometry, ophthalmology, biomedical engineering, and data science to address critical questions in myopia research. Current projects focus on understanding the mechanisms of atropine's myopia control effects, developing advanced imaging biomarkers for myopia progression, and investigating the impact of modern visual environments on eye development.
David E. Carr serves as a Research Professor in the Department of Environmental Sciences at the University of Virginia, conducting field-based evolutionary ecology research with emphasis on plant genetic systems. Education: Ph.D. from University of Maryland (1990) His research program integrates population genetics and ecological dynamics to investigate inbreeding consequences in plant-pollinator-herbivore networks and invasive species establishment mechanisms. Methodologically grounded in quantitative genetics, his work employs controlled greenhouse trials and natural population field studies across diverse ecosystems. Current projects examine stressor interactions (drought, nutrient shifts) in plant competitive hierarchies and genetic mediation of defense traits. Analysis of his 2015-2018 publications reveals consistent focus on anthropogenic disturbance impacts: 70% address invasive species management, 60% explore abiotic stress responses (drought/nitrogen), and 40% investigate genetic mechanisms in plant-herbivore systems. Key journals include Plant and Soil, Forests, and Ecology and Evolution, demonstrating interdisciplinary reach across plant physiology, restoration ecology, and invasion biology. Research operations are centered at UVA's Blandy Experimental Farm, where field plots and greenhouse facilities support experimental studies on plant competitive dynamics and stress adaptations. No verifiable information exists regarding graduate student mentorship or extramural grant funding in the provided materials.
Priv.-Doz. Dr. Andrea Zurl is a Research Associate at the University of Salzburg's Department of Ophthalmology, specializing in Experimental Ophthalmology and Glaucoma Research. With 86 peer-reviewed publications and 9 funded projects, her work focuses on retinal immunology, vascular degeneration, and pericyte biology. Glaucoma pathophysiology Retinal vascular remodeling Leukotriene receptor mechanisms Corneal regeneration techniques Alzheimer's disease ocular manifestations Recent articles demonstrate expertise in neuroimmune interactions (2025), gut-brain axis modulation (2025), and advanced imaging of optic nerve repair (2023). Current projects investigate pericyte-targeted therapies for neuroregeneration and diabetic retinal degeneration timelines.
Charles Andrew Czeisler is the Frank Baldino, Jr., Ph.D. Professor of Sleep Medicine at Harvard Medical School, with clinical appointments at Brigham and Women's Hospital Division of Sleep and Circadian Disorders. He directs significant research initiatives including the Sleep Matters Initiative at Brigham Health and co-founded the Harvard Work Hours Health and Safety Group. His work bridges basic circadian science with clinical applications and public health policy. Dr. Czeisler completed his A.B. magna cum laude in Biochemistry and Molecular Biology at Harvard College (1974), followed by a Ph.D. in Neuro- and Biobehavioral Sciences at Stanford University (1978) under William C. Dement, an M.D. from Stanford University School of Medicine (1981), and a Senior Fellowship in Health Policy at Harvard's Kennedy School of Government (1983). His laboratory research focuses on the neurobiology of the human circadian pacemaker in the suprachiasmatic nucleus and its interaction with the sleep homeostat. Current investigations examine melatonin's role in sleep organization, photic resetting mechanisms through intrinsically photosensitive retinal ganglion cells containing melanopsin, and how circadian/homeostatic processes regulate sleep and neurobehavioral function. His team studies novel wake-promoting countermeasures, exercise effects on circadian rhythms, fMRI of sleep-deprived brains, aging influences on sleep, chronic sleep restriction impacts, and space flight effects on circadian rhythms. Analysis of Dr. Czeisler's recent publications reveals a strong emphasis on translational research connecting basic circadian science with clinical applications. His work increasingly examines sleep's relationship with long COVID, mental health, occupational safety (particularly for medical residents and transportation workers), and technological approaches to sleep assessment. The research demonstrates growing interdisciplinary collaboration across sleep medicine, public health, digital health technology, and policy development. Aschoff's Rule International Award in Circadian Biology (2001) Lifetime Achievement Award, National Sleep Foundation (2008) Lord Adrian Gold Medal, Royal Society of Medicine (2008) Election to National Academy of Medicine (2010) NASA Johnson Space Center Director's Innovation Award (2014) Peter C. Farrell Prize in Sleep Medicine (2019) Establishment of Annual Charles A. Czeisler Lectureship, Monash University (2023) Sleep Hero Award (2024) Dr. Czeisler has mentored numerous researchers who have become leaders in sleep medicine, including Robbins, Weaver, Barger, Quan, and Duffy. His research is supported by multiple active grants including a $5.8 million Department of Defense project developing a blood test to measure sleep deprivation, an international task force on sleep/circadian rhythms and youth depression funded by Wellcome Trust, and clinical trials investigating treatments for shift work disorder. His work has directly influenced policies on medical resident work hours, airline crew scheduling, and daylight saving time. Dr. Czeisler leads the Division of Sleep and Circadian Disorders at Brigham and Women's Hospital and the Harvard Medical School Division of Sleep Medicine. Through the Sleep Matters Initiative, his team applies circadian research to night workers including medical residents and police. His laboratory collaborates with NASA on space flight circadian research and with the International Association of Circadian Health Clinics on global implementation of circadian medicine principles.
Nina Milosavljevic is a Lecturer in the Division of Neuroscience, focusing on retinal physiology, optogenetics, and the role of light in biological rhythms. Her work contributes to UN Sustainable Development Goals related to health and well-being. Research Interests: Vision systems, optogenetics, retinal ganglion cells, circadian rhythms, and light effects on behavior. Projects: Biological rhythms, sensory systems, and circadian timing mechanisms. Publications: Over 30 peer-reviewed articles, including studies on retinal cell types, ipRGC signaling, and optogenetic tools. Contributions: Dataset on G-protein signaling mechanisms and collaborative work on retinal degeneration. Labs/Teams: Involved in the Centre for Biological Timing and interdisciplinary projects on sensory systems and brain disorders.
Associate Professor Ulrike Grunert is a distinguished researcher in the Faculty of Medicine and Health at the University of Sydney, where she serves in the Clinical Ophthalmology and Eye Health department at the Save Sight Institute. With over three decades of experience in visual neuroscience, her work has significantly advanced our understanding of retinal structure and function. Dr. Grunert received her PhD in Biology from Johann Wolfgang Goethe University in Frankfurt, Germany in 1985, followed by postdoctoral work at the University of Florida. She became a group leader at the Max-Planck-Institute for Brain Research before joining the University of Sydney in 1994 with a Feodor Lynen fellowship from the Alexander von Humboldt Foundation. She was awarded her Habilitation from Goethe University in 1994 and has maintained continuous research activity since then, with appointments including Lions Vision Research Fellow (2003-2009) and Honorary Principal Research Fellow at the University of Melbourne (2006). Her research focuses on the functional neuroanatomy of the mammalian retina, with special emphasis on the primate retina. Dr. Grunert's work has been instrumental in defining the neural circuitry of the eye , particularly related to retinal ganglion cells and their connections with other retinal cells and targets in the brain. Her laboratory employs advanced techniques including immunohistochemistry, confocal microscopy, and single-cell transcriptomics to investigate retinal cell types and their functional organization. Analysis of her recent publications reveals a consistent research trajectory focused on characterizing retinal cell types across primate species, with increasing emphasis on molecular markers and comparative approaches. Her work spans from fundamental cellular organization to translational applications in vision science, with particular attention to the human fovea and specialized retinal pathways. Her scientific achievements have been recognized with prestigious awards including: National Vision Research Institute Fellowship (2020) Nina Kondelos Award of the Australian Neuroscience Society (2017) Sydney Medical Foundation Fellowship (2017-2021) Lions Vision Research Fellowship (2003-2009) Dr. Grunert has successfully supervised numerous students and collaborated extensively with international researchers. Her grant portfolio includes multiple NHMRC Project Grants, ARC Centre of Excellence funding, and equipment grants supporting advanced retinal imaging. She currently leads research on retinal gene therapy delivery, mapping the human retina, and night vision pathways, often in collaboration with international partners in Italy, Japan, and the United States. Her laboratory at the Save Sight Institute maintains state-of-the-art facilities for retinal histology, confocal microscopy, and molecular analysis.
Paulo Kofuji is an Associate Professor in the Department of Neuroscience at the University of Minnesota, College of Biological Sciences. His research is focused on the role of glial cells—particularly astrocytes and microglia—in brain function and neurological disorders. He is actively involved in multiple NIH-funded research projects and maintains a strong publication record in high-impact neuroscience journals. University: University of Minnesota School: College of Biological Sciences Department: Department of Neuroscience Position: Associate Professor Research Interests: Dr. Kofuji's work centers on glial cell biology, including astrocyte-neuron communication, calcium signaling, circadian regulation in glia, and the role of glia in neurodegenerative diseases such as Huntington’s disease and spinocerebellar ataxia. His early work on melanopsin-expressing retinal ganglion cells has contributed significantly to understanding non-image-forming vision and circadian photoentrainment. Publication Trends: His recent publications (2023–2025) highlight a strong focus on astrocyte-mediated synaptic plasticity, calcium dynamics in glia, and the impact of glial dysfunction in neurodevelopmental and neurodegenerative conditions. The research integrates molecular, cellular, and behavioral approaches, often using transgenic mouse models. Scientific Awards: No specific awards are mentioned in the provided text. Advising and Grants: While student names are not listed, Dr. Kofuji has mentored researchers involved in his publications. He has secured multiple NIH grants as both Principal Investigator and Co-Investigator, including projects on circadian clocks in glia, retinal ganglion cells, and glial dysfunction in Huntington’s and SCA1 diseases. Labs and Teams: Dr. Kofuji leads a research laboratory focused on glial physiology and collaborates extensively with prominent neuroscientists such as Alfonso Araque, Huda Zoghbi (via Orr), and Malvika Cvetanovic. His team investigates glial contributions to synaptic function, behavior, and disease mechanisms using advanced imaging, molecular biology, and behavioral assays.
Mark Hankins is a Professor of Visual Neuroscience and Associate Head of the Nuffield Laboratory of Ophthalmology (NLO) at the University of Oxford , with a Visiting Professor appointment in Bioengineering at Imperial College London . His career spans foundational research in visual physiology and translational optogenetics. Education: BSc in Biophysics PhD in Biophysics (Imperial College London) Research Interests focus on light-dependent signaling in the retina and brain, non-visual light detection , and melanopsin-based optogenetics for vision restoration. His work bridges retinal biology , regenerative medicine , and neurotechnology . Recent Publications (2025–2022) highlight advancements in optogenetic therapies for retinal degeneration, retinal remodeling, and translational challenges in prosthetic devices. Key themes include retinal prosthetics , gene therapy , and neural engineering . Scientific Awards include Wellcome Trust Vision Fellowship Grants from MRC, BBSRC, and Hoffman-La Roche Students and Collaborators include postdoctoral researchers and doctoral candidates funded by Wellcome Trust , BBSRC , and EPSRC . He leads the Retinal Neurobiology and Optogenetics Group at Oxford, with collaborations at Cambridge and Manchester .
Peter Light is a Full Professor in the Department of Pharmacology within the Faculty of Medicine and Dentistry at the University of Alberta. He serves as Chair of Pharmacology (since July 2023) and Director of the Alberta Diabetes Institute (since July 2010). He holds the prestigious Dr. Charles A. Allard Chair in Diabetes Research and leads an active research laboratory located in the Alberta Diabetes Institute. BSc-Honours (Biological Sciences/Cell Physiology), University of Birmingham, UK, 1986 PhD (Biological Sciences/Cell Physiology), University of Birmingham, UK, 1990 Post-doctoral training at University of Calgary and University of Ottawa Dr. Light's research focuses on molecular pharmacology and new therapeutics for diabetes and heart disease. His laboratory investigates ion transport processes controlling cellular excitability using electrophysiological, live-cell imaging, biochemical and molecular techniques. Current research areas include ionic and metabolic events leading to cellular dysfunction in the heart and endocrine pancreas, incretin biology in pancreatic islets, development of small molecules for treating heart failure and diabetes, ATP-sensitive potassium channel function, anti-diabetic drug safety, and non-invasive glucose monitoring systems. His lab has pioneered research on endogenous light-sensitive signaling pathways in adipocytes and optogenetic applications for diabetes treatment. Analysis of Dr. Light's recent publications reveals a strong focus on the intersection of diabetes and cardiovascular disease, particularly the cardiac effects of SGLT2 inhibitors. His work spans from molecular studies of ion channels to clinical applications of diabetes medications, with increasing emphasis on novel glucose monitoring technologies and optogenetic approaches for metabolic disorders. Dr. Charles A. Allard Chair in Diabetes Research Dr. Light's research program is funded by the Canadian Institutes of Health Research and the Alberta Diabetes Foundation. He has mentored numerous graduate students, post-doctoral fellows, and research associates across multiple projects. His laboratory team includes specialists in electrophysiology, molecular biology, and biomedical engineering working collaboratively on diabetes and cardiovascular research. The Light Lab is part of the Alberta Diabetes Institute, a world-class research facility housing the IsletCore human islet isolation and research facility that Dr. Light helped establish in 2010 with joint funding from the Alberta Diabetes Foundation and the University of Alberta. Dr. Light's laboratory occupies space in the Li Ka Shing Centre, with both office (6-126A) and lab (6-040) facilities. The lab maintains an active presence through its website (thelightlab.ca) and continues to recruit highly qualified researchers for positions in diabetes and cardiovascular pharmacology.
Kwoon Wong is an Associate Professor at the University of Michigan, holding dual appointments in Molecular, Cellular, and Developmental Biology (MCDB) and Ophthalmology and Visual Sciences. He leads research on intrinsically photosensitive retinal ganglion cells (ipRGCs), focusing on non-image-forming visual processes such as circadian rhythms and light-induced alertness. His work combines electrophysiology, microscopy, and behavioral assays to study ipRGC function, interactions with retinal neurons, and applications in therapies for sleep disorders and blindness. Education: PhD in Biology from Harvard University (2003), Postdoctoral training at Brown University. Research Areas: Retinal physiology, circadian photoentrainment, light therapy development, and retinal prosthesis strategies. Dr. Wong collaborates with multiple labs to investigate retinal degeneration therapies, glia-derived neurons, and visual signaling in demyelination models. His lab’s long-term goals include advancing lighting technologies, drug therapies, and assistive devices for vision impairment.
Ajith Karunarathne, Ph.D., is an Associate Professor of Chemistry at Saint Louis University, affiliated with the School of Science and Engineering. His research focuses on Biological Chemistry, Chemical Biology, and Molecular Pharmacology, with a particular emphasis on optogenetic tools and G protein signaling. He earned his Ph.D. in Biological Chemistry from Michigan State University and completed postdoctoral training in Signal Transduction and Optogenetics at Washington University School of Medicine. Education: Ph.D. in Biological Chemistry, Michigan State University Postdoctoral Training in Signal Transduction and Optogenetics, Washington University School of Medicine His research group investigates subcellular signaling mechanisms, optogenetic tool development, and the interplay between light, retinal, and cellular toxicity. Key projects include engineering opsins for in vivo applications, studying G protein signaling pathways, and exploring phytopharmacology for targeted drug delivery. His work bridges molecular biology with pharmacology, aiming to uncover disease mechanisms and develop therapeutic strategies. Publications highlight his contributions to understanding G protein dynamics, optogenetic methodologies, and light-induced toxicity. While no formal awards are listed, his extensive publication record reflects his scholarly impact. Advising and grants are not explicitly detailed, but his research involves collaboration with institutions like Washington University and SLU labs. His lab focuses on interdisciplinary approaches to signaling and pharmacological innovation.
Paul Franken is an Associate Professor at the Center for Integrative Genomics (CIG), University of Lausanne. His research focuses on the molecular mechanisms underlying sleep homeostasis and circadian rhythms, with emphasis on genetic and systems-level approaches. Franken received his PhD from the University of Groningen (1993) and conducted postdoctoral work at Stanford University and the University of Geneva. His lab investigates how sleep-wake states interact with circadian processes, using mouse models to study clock gene regulation, miRNA functions, and the genetic basis of EEG traits. Key projects include systems genetics of sleep deprivation and the role of NPAS2 in linking clock genes to metabolic state. Education: PhD in Neurobiology, University of Groningen (1993) Postdoctoral Training: Stanford University (1993–2000), University of Geneva (1996–2000) Affiliations: Member of the CIG since 2005; Group Leader with postdocs, PhD students, and technical staff Research Interests: The lab employs QTL mapping, molecular genetics, and in vivo imaging to unravel how sleep homeostasis and circadian rhythms are intertwined. Current projects explore: Genetic determinants of sleep traits using BXD and Collaborative Cross mouse populations Mechanisms linking clock gene expression (e.g., PER1/PER2) to wakefulness duration Role of miRNAs like miR-709 in sleep EEG regulation Systems biology approaches to integrate genomic, metabolomic, and behavioral data Grants & Collaborations: Supported by Swiss National Science Foundation and EU grants. Collaborates with neuroscientists, bioinformaticians, and clinicians to advance sleep medicine. Labs/Teams: Franken leads a multidisciplinary team at CIG, including studies on vestibular stimulation effects (rocking and sleep) and peripheral clock interactions.
